REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
REGENXBIO (RGNX) has announced upcoming presentations of new interim biomarker data from their Phase I/II AFFINITY DUCHENNE® trial of RGX-202, a treatment for Duchenne muscular dystrophy.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO (RGNX) has announced upcoming presentations of new interim biomarker data from their Phase I/II AFFINITY DUCHENNE® trial of RGX-202, a treatment for Duchenne muscular dystrophy. The data will be presented at the 2025 MDA Clinical & Scientific Conference in Dallas from March 16-19, 2025.
Two presentations are scheduled: An interim clinical data presentation by Dr. Carolina Tesi Rocha from Stanford School of Medicine on March 19, and a pre-clinical research presentation on microdystrophin by Dr. Steven Foltz, Senior Scientist at REGENXBIO. Both presentations will be made available on REGENXBIO's website.
Details
News Market Reaction – RGNX
The recorded move for RGNX in the trading session of this news was -5.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Title: RGX-202, an investigational gene therapy for the treatment of Duchenne Muscular Dystrophy: Interim clinical data (O75)
Session: Clinical Trials
Date/Time: Wednesday, March 19, 2025; 8:15 a.m. CT
Presenter: Carolina Tesi Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children's Health
Title: Enhanced therapeutic potential of a microdystrophin with an extended C-terminal domain (P143)
Session: Pre-Clinical Research
Presenter: Steven Foltz, Ph.D., Senior Scientist, Research & Early Development at REGENXBIO
The presentations will be available in the Publications section of REGENXBIO's website.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-2025-muscular-dystrophy-association-mda-clinical--scientific-conference-302396530.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.